SequelSEC

NEXGEL, INC. NXGL

Surgical & Medical Instruments & Apparatus · CIK 0001468929 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$11.42M
Fiscal year ended 2025-12-31
Operating income
-$3.35M
Fiscal year ended 2025-12-31
Free cash flow
-$1.38M
Fiscal year ended 2025-12-31

NEXGEL, INC. (NXGL) reported revenue of $11.42M and net income of -$3.00M for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from NEXGEL, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

NEXGEL, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$11.42M$8.69M$4.09M$2.05M$1.55M$674.00K$717.00K$2.21M
Cost of revenue$6.91M$5.94M$3.72M$1.79M$1.54M$965.00K$854.00K$1.70M
Gross profit$4.51M$2.75M$374.00K$256.00K$8.00K-$291.00K-$137.00K$514.00K
Operating income-$3.35M-$3.55M-$3.48M-$3.35M-$2.57M-$2.26M-$1.92M-$1.89M
Net income-$3.00M-$3.28M-$3.16M-$4.75M-$4.31M-$2.26M-$1.92M-$1.89M
Research & development$2.00K$78.00K$103.00K$367.00K$31.00KUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 7.85Mshares 6.51Mshares 5.67Mshares 5.57Mshares 2.98Mshares 2.25Mshares 13.57Mshares 5.01M
Pretax income-$2.89M-$3.46M-$3.19M-$4.75MUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailable$0$0$0$0Unavailable
Diluted EPS$-0.38$-0.50$-0.56$-0.85$-1.45$-1.05$-0.14$-0.38
Selling, general & administrative$7.86M$6.22M$3.75M$3.24M$2.55M$1.97M$1.79M$2.40M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

NEXGEL, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalentsUnavailable$1.81M$2.70MUnavailable$13.35M$32.00K$261.00K$0
Total assets$10.46M$10.98M$9.96M$10.36M$16.98M$2.26M$1.89M$739.00K
Current assets$4.34M$5.11M$5.05M$7.50M$13.93M$363.00K$513.00K$361.00K
Total liabilities$5.57M$4.90M$4.79M$2.72M$4.90M$2.19M$1.51M$458.00K
Current liabilities$2.96M$2.47M$2.55M$859.00K$2.89M$1.33M$800.00K$407.00K
Total equity incl. NCI$4.89M$6.08M$5.17M$7.64M$12.08M$71.00K$380.00K$281.00K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$2.11M$1.75M$1.32M$502.00K$291.00K$233.00K$113.00K$101.00K
Accounts receivable$673.00K$933.00K$633.00K$222.00K$209.00K$73.00K$102.00K$34.00K
Goodwill$1.13M$1.13M$1.13M$311.00K$311.00K$311.00K$0Unavailable
Long-term debt$588.00K$685.00K$593.00K$283.00KUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailable$1.23M$265.00K$254.00K$658.00K$510.00K$157.00K

Cash flow

NEXGEL, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow-$1.31M-$3.87M-$3.24M-$2.99M-$2.75M-$1.80M-$1.81M-$1.54M
Capital expenditures$68.00K$443.00K$696.00K$96.00K$269.00K$312.00K$0Unavailable
Investing cash flow-$68.00K-$775.00K$4.46M-$5.60M-$269.00K-$312.00K$0Unavailable
Financing cash flow$630.00K$3.75M$379.00K-$3.66M$16.34M$1.88M$2.08M$1.54M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$654.00K$367.00K$217.00K$298.00K$285.00K$232.00K$4.00K$0
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$450.00K$436.00K$226.00K$112.00K$113.00K$50.00K$67.00K$322.00K

Derived

NEXGEL, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flow-$1.38M-$4.31M-$3.93M-$3.09M-$3.02M-$2.11M-$1.81MUnavailable
Gross margin39.5%31.6%9.1%12.5%0.5%-43.2%-19.1%23.2%
Operating margin-29.3%-40.9%-85.0%-163.5%-165.7%-335.3%-268.3%-85.3%
FCF margin-12.1%-49.6%-96.2%-150.8%-194.8%-313.5%-253.0%Unavailable
SBC / revenue5.7%4.2%5.3%14.6%18.4%34.4%0.6%0.0%
Current ratio1.47x2.07x1.98x8.74x4.82x0.27x0.64x0.89x
Revenue YoY growth31.5%112.5%99.7%32.0%130.1%-6.0%-67.6%Unavailable
Net margin-26.3%-37.8%-77.2%-231.7%-277.9%-335.9%-268.2%-85.3%
R&D / revenue0.0%0.9%2.5%17.9%2.0%UnavailableUnavailableUnavailable
CapEx / revenue0.6%5.1%17.0%4.7%17.3%46.3%0.0%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NXGL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-17View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.